logo.jpg
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting
26. November 2024 05:00 ET | ImCheck Therapeutics SAS
ImCheck to Present Encouraging Interim Results in AML Patients from the EVICTION Trial at the 66th American Society of Hematology Annual Meeting Marseille, France, November 26, 2024, 11 am CET –...
oxb new logo.png
Interim Results for the Six Months Ended 30 June 2024
23. September 2024 08:42 ET | OXB
Press release OXFORD BIOMEDICA PLCINTERIM RESULTS FOR THE SIX MONTHS ENDED 30 JUNE 2024 Delivering Pure-Play CDMO Growth Strategy Continued execution of "One OXB" strategy with global integration...
THERALINK_LO_FF_BLUE.png
Theralink® Announces Promising Interim Results on the Implementation of Proteomic Analysis into Inova Schar Cancer Institute’s Molecular Tumor Board
03. November 2023 09:15 ET | Theralink Technologies, Inc.
Golden, Colorado, Nov. 03, 2023 (GLOBE NEWSWIRE) -- Theralink Technologies, Inc. (OTC: THER) (“Theralink”), a precision oncology company with its exclusive commercial RPPA (reverse phase protein...
LOGO.png
Nemaura Medical Completes 100 Patient Study for sugarBEAT® 24-hour Wear and Reports Interim Results
11. September 2023 09:00 ET | Nemaura Medical, Inc
LOUGHBOROUGH, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Nemaura Medical, Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing and commercializing...
lithiumlogo.jpg
Standard Lithium Reports Fiscal Second Quarter 2023 Results, Furthers Progress on Path Toward Commercial Development
09. Februar 2023 10:04 ET | Standard Lithium
VANCOUVER, British Columbia, Feb. 09, 2023 (GLOBE NEWSWIRE) -- Standard Lithium Ltd. (“Standard Lithium” or the “Company”) (TSXV: SLI) (NYSE American: SLI) (FRA: S5L), a leading near-commercial...
Allergy.png
Interim Results for the six months ended 31 December 2021
03. März 2022 07:00 ET | Allergy Therapeutics
Allergy Therapeutics plc(“Allergy Therapeutics” or the “Company” or the “Group”) Interim Results for the six months ended 31 December 2021 ~ US readiness plan underway including two...
synairgen.png
Interim results for the six months ended 30 June 2021
30. September 2021 07:00 ET | Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
synairgen.png
Interim results for the six months ended 30 June 2021
30. September 2021 02:01 ET | Synairgen plc
Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2021 Scaling up and preparing for Phase III COVID-19 trial data read-out Webcast today at 13:00 BST ...
synairgen.png
Synairgen plc - Interim results for the six months ended 30 June 2020
29. September 2020 07:00 ET | Synairgen plc
Press release Synairgen plc(‘Synairgen’ or the ‘Company’) Interim results for the six months ended 30 June 2020 Southampton, UK – 29 September 2020: Synairgen plc (LSE: SNG), the respiratory drug...
Ergomed logo1.PNG
Ergomed plc Interim results for the six months ended 30 June 2020
22. September 2020 07:00 ET | Ergomed plc
PRESS RELEASE Interim results for the six months ended 30 June 2020 Services strategy drives revenue and profit growthOrder book growth underpins high forward visibility Total revenue growth of...